Song N, Liu ZS, Xue W, Bai ZF, Wang QY, Dai J, Liu X, Huang YJ, Cai H, Zhan XY, Han QY, Wang H, Chen Y, Li HY, Li AL, Zhang XM, Zhou T, Li T. NLRP3 Phosphorylation Is an Essential Priming Event for Inflammasome Activation. Mol Cell. 2017 Sep 19; PubMed.

Recommends

Please login to recommend the paper.

Comments

  1. I don’t know how bioavailable the boron compounds will be in the CNS, but the safety profile associated with targeting NLRP3 should be quite good. There are currently five companies that have been formed to make NLRP3 inhibitors, in the hope of getting them into the clinic, although perhaps Alzheimer’s is not the first indication they will target.

    View all comments by Seth Masters

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. New AD Target: Silencing the NLRP3 Inflammasome with Boron?